Vicore Pharma publish annual report for 2017

Vicore Pharma Holding (publ) (ticker: VICO) can today announce that the annual report for 2017 is now available on the company's website; www.vicorepharma.com

2017 in brief

• Focused strategy in fibrotic diseases in the orphan drug field

• Strong safety data for C21 in Phase I applications

• Strengthened organization introducing new expertise

• Further development of C21 for additional fibrous diseases

• New collaboration with CRO for continued clinical program

Changes in results from previously published year-end report

• Reclassification of the holding in I-Tech to an associated company was reported in the year-end report as a capital loss. In the annual report this has been changed to being treated as a goodwill with a depreciation period of 5 years.

• Additional write-downs of patents of 3 789 KSEK  from previously published financial statements.

KSEK  2017  2016  2015  2014 
Operating profit/loss  -12 793  -6 649  -4 543  -5 340 
Profit/Loss after financial items  -12 855  -6 652  -4 570  13 687 
Earnings per share, SEK  -1,40  -0,54  -0,37  0,20 
Total equity as of 31 December  112 968  75 597  81 930  53 696 
Cash flow from operating activities  -7 704  -7 251  -3 682  -2 825 
Cash flow from investing activities  -22 779  -13 977  -5 657  -2 390 
Cash and cash equivalents at year end  24 019  4 266  25 175  1 710 

For more information, please contact:

Per Jansson, CEO
M:+46 (0)70 917 47 46
per.jansson@vicorepharma.com  

Hans Jeppsson, CFO
M: +46 (0)70 553 14 65
hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09.00 CET on April 12, 2018

About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see  www.vicorepharma.com

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links